Novo Nordisk selects insider as new CEO to tackle ‘recent market challenges’

The corporate confronted the growing reverse winds in the primary American pharmaceutical market, as the 2 medicine, often known as GLP-1 injection, witnessed their dominance, which was stabbed by opponents, together with Eli Lily.

Novo mentioned a rule by the American Meals and Drug Administration that permits pharmacies to create the so -called “car” of the drug after the excessive demand led to a scarcity of earnings.

“Regardless of the tip of the FDA to multiply interval on Might 22, 2025, Novo Nordisk market reveals that the unrealistic and unlawful collective compound has continued,” she mentioned in an announcement.

You are actually anticipating gross sales in your entire 12 months from eight to 14 p.c, a lower from 13 to 21 p.c anticipated after the primary expectations had been decreased earlier this 12 months.

Operation margins are seen as much as 10 to 16 p.c, as a substitute of 16 to 24 p.c expectations.

The low expectations got here at a time when Novo knowledgeable on Tuesday a rise of 18 p.c gross sales for the primary half of the 12 months, whereas working revenue development decreased to 29 p.c after 40 p.c development in the identical interval final 12 months.

“Market Challenges” prompted in Might to announce the departure of the CEO of Lars Fergard Yorgensen, who will likely be changed by Mike Dosdar, the present vice chairman of worldwide operations.

“We’re assured that he’s the very best particular person to guide Novo Nordisk throughout the subsequent development part,” Hilg Lund, Chairman of the Board of Administrators, mentioned in an announcement.

“This is a vital second for Nofu Nordsk,” Lund mentioned. “The market is creating rapidly, and the corporate must face the challenges of the final market at pace and ambition.”

The total outcomes of the Novo Nordisk will likely be revealed within the first half on August 6.